Loading...

PE anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_53-6dot7_PE_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 1_53-6dot7_PE_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 2_53-67_PE_CD8a_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD8a (clone 53-6.7) PE (solid line) or rat IgG2a, κ PE isotype control (dashed line).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100707 50 µg 30€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100708 200 µg 86€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  2. Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed
  3. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  4. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  5. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  6. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  7. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  8. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  9. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  10. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  11. Manukian G, et al. 2021. Int J Radiat Oncol Biol Phys. 110:1341. PubMed
  12. Chen X, et al. 2009. Hum Immunol. 70:79. PubMed
  13. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  14. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  15. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  16. Sng XYX, et al. 2020. J Immunol. 204:3108. PubMed
  17. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  18. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  19. Hu HJ, et al. 2020. Cell Death Dis. 1.168055556. PubMed
  20. Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed
  21. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  22. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  23. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  24. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  25. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  26. Diao L, et al. 2022. iScience. 25:105511. PubMed
  27. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  28. Liu W, et al. 2021. Cell Mol Immunol. 18:2660. PubMed
  29. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  30. Wong J, et al. 2015. Elife. 3: 07839. PubMed
  31. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  32. He Y, et al. 2020. Sci Adv. 6:eaba7589. PubMed
  33. Zhao B, et al. 2020. Nat Commun. 11:908. PubMed
  34. van Erp EA, et al. 2019. Viruses. 0.811111111. PubMed
  35. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  36. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  37. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  38. Tian X, et al. 2022. Front Immunol. 13:875236. PubMed
  39. N'guessan P, et al. 2011. Antioxid Redox Signal. 15:1693. PubMed
  40. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  41. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  42. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  43. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  44. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  45. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  46. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  47. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  48. Uchida A, et al. 2021. J Inflamm Res. 14:3089. PubMed
  49. Jia L, et al. 2022. Front Immunol. 13:897879. PubMed
  50. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  51. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  52. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  53. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  54. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  55. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  56. Lo W, Allen D 2012. Nat Immunol. 13:880. PubMed
  57. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  58. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  59. Morabito KM, et al. 2017. Mucosal Immunol. 0.795138889. PubMed
  60. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  61. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  62. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  63. Dang Y, et al. 2022. Cancer Cell Int. 22:88. PubMed
  64. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  65. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  66. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  67. Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed
  68. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  69. Levine LS, et al. 2021. Immunity. 54(4):829-844.e5. PubMed
  70. Perry JSA, et al. 2018. Immunity. 48:923. PubMed
  71. Li J, et al. 2019. JCI Insight. 5. PubMed
  72. Meyer LK, et al. 2019. J Clin Invest. 130:863. PubMed
  73. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  74. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  75. Yang R, et al. 2022. Front Pharmacol. 13:774440. PubMed
  76. Hu G, et al. 2022. Cell Death Dis. 13:640. PubMed
  77. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  78. Frazier T, et al. 2018. Adipocyte. 0.41875. PubMed
  79. Naing A et al. 2019. Cell reports. 26(5):1242-1257 . PubMed
  80. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  81. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  82. Sá da Bandeira D, et al. 2022. Cell Rep. 40:111114. PubMed
  83. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  84. Yang H, et al. 2022. Nutrients. 14:. PubMed
  85. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  86. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  87. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  88. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  89. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  90. Lee CG, et al. 2019. JCI Insight. 4:5. PubMed
  91. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  92. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  93. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  94. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  95. James OJ, et al. 2021. Nat Commun. 12:4290. PubMed
  96. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  97. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  98. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  99. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  100. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  101. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  102. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  103. Cho K, et al. 2021. iScience. 24:103117. PubMed
  104. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  105. Zhao X, et al. 2013. Int Immunopharmacol. 17:793. PubMed
  106. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  107. Schuldt N, et al. 2015. PLoS One. 10: 0145762. PubMed
  108. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  109. Guo C, et al. 2017. Methods Mol Biol. 1709:345. PubMed
  110. Burr ML, et al. 2019. Cancer Cell. 36:385. PubMed
  111. Loh Z, et al. 2020. PLOS Pathogens. 16(7):e1008651. PubMed
  112. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  113. Chan WF, et al. 2022. Nat Commun. 13:5582. PubMed
  114. Moutuou MM, et al. 2020. Methods Mol Biol. 2111:267. PubMed
  115. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  116. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  117. Lin J, et al. 2021. Nat Commun. 12:5321. PubMed
  118. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  119. Monaghan KL, et al. 2020. J Vis Exp. . PubMed
  120. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  121. Thomas AM, et al. 2020. Journal of Cellular Physiology. 235(6):5120-5129.. PubMed
  122. Manrique-Rincón A, et al. 2017. Front Immunol. 10.3389/fimmu.2017.01150. PubMed
  123. Watson MJ, et al. 2021. Nature. 591:645. PubMed
  124. Wu S, et al. 2021. Nat Cancer. 2:189. PubMed
  125. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  126. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  127. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  128. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  129. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  130. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  131. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  132. Echevarría-Vargas IM, et al. 2018. EMBO Mol Med. 10:e8446. PubMed
  133. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  134. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  135. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  136. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  137. Shen DD, et al. 2022. Mol Cancer. 21:75. PubMed
  138. Zhu J, et al. 2021. Cancer Cell Int. 21:529. PubMed
  139. Baranwal G, et al. 2021. Physiol Rep. 9:e15094. PubMed
  140. Bristow CL, et al. 2021. Front Oncol. 11:739080. PubMed
  141. Li J, et al. 2020. Development. :. PubMed
  142. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  143. Li J, et al. 2020. FASEB J. 34:3091. PubMed
  144. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  145. Rodriguez-Sosa M, et al. 2004. Infect Immun. 72:4552. PubMed
  146. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  147. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  148. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  149. Zhang J, et al. 2018. Nature. 553:91. PubMed
  150. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  151. Tsai SJ, et al. 2021. J Biol Chem. 297:101266. PubMed
  152. Pai M, et al. 2016. JPEN J Parenter Enteral Nutr. 40: 383 - 391. PubMed
  153. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  154. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  155. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  156. Eisemann T, et al. 2019. Front Oncol. 9:187. PubMed
  157. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  158. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  159. Koide S, et al. 2022. iScience. 25:103603. PubMed
  160. Kline JM, et al. 2021. J Biol Chem. :100373. PubMed
  161. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  162. Ene CI, et al. 2020. Neuro Oncol. 639:22. PubMed
  163. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  164. Xu C, et al. 2020. Immunity. 53(2):417-428.e4. PubMed
  165. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  166. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  167. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  168. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  169. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  170. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  171. Wu G, et al. 2021. Nat Cancer. 2:1170. PubMed
  172. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  173. Schnoegl D, et al. 2022. Front Immunol. 13:909270. PubMed
  174. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  175. Wong L, et al. 2013. J Biol Chem. 288:35170. PubMed
  176. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  177. Wu Y, et al. 2015. J Immunol. 195: 2612-2623. PubMed
  178. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  179. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  180. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  181. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  182. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  183. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  184. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  185. Chavez JS, et al. 2022. Cells. 11:. PubMed
  186. Wang X, et al. 2022. Elife. 11:. PubMed
  187. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  188. Wang X, et al. 2021. Theranostics. 11:209. PubMed
  189. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  190. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  191. LeBlanc P, et al. 2014. J Biol Chem. 289:7777. PubMed
  192. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  193. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  194. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  195. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  196. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  197. Gawish R, et al. 2022. Elife. 11:. PubMed
  198. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  199. Kang YA, et al. 2020. J Exp Med. 217:00:00. PubMed
  200. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  201. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  202. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  203. Zeng A, et al. 2020. Oncol Rep. . PubMed
  204. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  205. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  206. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  207. Pastor Arroyo EM, et al. 2022. Clin Sci (Lond). 136:557. PubMed
  208. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  209. Lv K, et al. 2021. Cell Stem Cell. 28(7):1275-1290.e9. PubMed
  210. Yang E, et al. 2015. Acta Biochim Biophys Sin. 47: 588-596. PubMed
  211. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
  212. Lee YT, et al. 2018. PLoS One. 13:e0190868. PubMed
RRID
AB_312746 (BioLegend Cat. No. 100707)
AB_312747 (BioLegend Cat. No. 100708)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01-21-2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account